Abstract |
Preemptive skin treatment led by nurses and pharmacists was started for patients with metastatic colorectal cancer (mCRC)who received anti-EGFR antibody treatment. Incidence of skin-related toxicities, amount of topical moisturizers used, and administered cycles of anti-EGFR antibody were retrospectively compared between a preemptive skin treatment group and a control group. Thirty-four mCRC patients before the introduction of preemptive skin treatment led by nurses and 23 mCRC patients treated with preemptive skin treatment led by nurses were evaluated. The incidence of 6- and 12- week Grade 2 or higher skin-related toxicity was 23.5% in the control group and 8.7% in the preemptive group(p=0.18), and 67.7% in the control group and 30.4% in the preemptive group(p=0.0076), respectively. Mean amounts of moisturizer used were both lower in the control group than in the preemptive group at both 6 weeks and 7-12 weeks(6 weeks; 275 g vs 550 g, p=0.036, 7-12 weeks; 575 g vs 1,175 g, p=0.013). However, the amount of topical steroid used was similar in both groups. Preemptive moisturizer skin treatment led by nurses and pharmacists may decrease the incidence of skin- related toxicity.
|
Authors | Mayumi Hirata, Tomoko Demachi, Toshinori Yanagawa, Akihiko Yarimizu, Kayo Nomura, Miyu Kuribayashi, Kei Kimura, Naohito Beppu, Jihyung Song, Yuya Takenaka, Yumiko Nishimura, Takeshi Kimura, Motoi Uchino, Hiroki Ikeuchi, Makoto Nagai, Masataka Ikeda, Kozo Kataoka |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 49
Issue 4
Pg. 421-424
(Apr 2022)
ISSN: 0385-0684 [Print] Japan |
PMID | 35444126
(Publication Type: Journal Article)
|
Chemical References |
- Panitumumab
- ErbB Receptors
- Cetuximab
|
Topics |
- Cetuximab
- Colonic Neoplasms
- Colorectal Neoplasms
(drug therapy, pathology)
- ErbB Receptors
- Humans
- Panitumumab
(adverse effects)
- Pharmacists
- Retrospective Studies
- Skin Diseases
(chemically induced)
|